215 related articles for article (PubMed ID: 1647965)
1. Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP.
Gray SJ; Heptinstall S
Eur J Pharmacol; 1991 Feb; 194(1):63-70. PubMed ID: 1647965
[TBL] [Abstract][Full Text] [Related]
2. DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect.
Jackson C; Ball J; Peel J; Lawry J; Greaves M; Preston FE
Thromb Haemost; 1989 Apr; 61(2):266-9. PubMed ID: 2546286
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation.
Rickards KJ; Andrews MJ; Waterworth TH; Alexander GB; Cunningham FM
J Vet Pharmacol Ther; 2003 Aug; 26(4):277-82. PubMed ID: 12887610
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro.
Azuma H; Takashima Y; Ishikawa M; Yamakado T
Jpn J Pharmacol; 1984 Feb; 34(2):159-70. PubMed ID: 6205194
[TBL] [Abstract][Full Text] [Related]
5. PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.
Glenn JR; White AE; Iyu D; Heptinstall S
Platelets; 2012; 23(5):344-51. PubMed ID: 22436052
[TBL] [Abstract][Full Text] [Related]
6. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
Liao CH; Tzeng CC; Teng CM
Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
[TBL] [Abstract][Full Text] [Related]
7. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E2 both stimulates and inhibits adenyl cyclase on platelets: comparison of effects on cloned EP4 and EP3 prostaglandin receptor subtypes.
Mao GF; Jin JG; Bastepe M; Ortiz-Vega S; Ashby B
Prostaglandins; 1996 Sep; 52(3):175-85. PubMed ID: 8908618
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues.
Matthews JS; Jones RL
Br J Pharmacol; 1993 Feb; 108(2):363-9. PubMed ID: 8448586
[TBL] [Abstract][Full Text] [Related]
10. Possible Contribution of Prostaglandin E2 to the antiproliferative effect of phosphodiesterase 4 inhibitors in human mononuclear cells.
Banner KH; Hoult JR; Taylor MN; Landells LJ; Page CP
Biochem Pharmacol; 1999 Nov; 58(9):1487-95. PubMed ID: 10513992
[TBL] [Abstract][Full Text] [Related]
11. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.
Turner NC; Wood LJ; Burns FM; Gueremy T; Souness JE
Br J Pharmacol; 1993 Apr; 108(4):876-83. PubMed ID: 8387385
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclic AMP phosphodiesterase activity of human blood platelet membrane by ADP.
Kahn NN; Sinha AK
Biochim Biophys Acta; 1989 Aug; 984(1):113-8. PubMed ID: 2548620
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic nipecotamide increases cyclic AMP levels and inhibits protein phosphorylation in human platelets.
Handa RK; Dillingham EO; Gollamudi R
Life Sci; 1995; 57(10):983-8. PubMed ID: 7643723
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP.
Haslam RJ; Davidson MM; Desjardins JV
Biochem J; 1978 Oct; 176(1):83-95. PubMed ID: 215136
[TBL] [Abstract][Full Text] [Related]
16. Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors.
Ezeamuzie CI
Eur J Pharmacol; 2001 Apr; 417(1-2):11-8. PubMed ID: 11301054
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the inhibitory effects of PGE2 and selective EP agonists on chemotaxis of human neutrophils.
Armstrong RA
Br J Pharmacol; 1995 Dec; 116(7):2903-8. PubMed ID: 8680723
[TBL] [Abstract][Full Text] [Related]
18. Azelastine potentiates the prostaglandin-induced increase of cyclic AMP content in human platelets and in guinea-pig alveolar macrophages.
Hatmi M; Havet N; Vargaftig BB; Bachelet M
Prostaglandins; 1992 May; 43(5):457-72. PubMed ID: 1374922
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
20. Cyclic AMP turnover in response to prostaglandins in intact platelets: evidence for separate stimulatory and inhibitory prostaglandin receptors.
Ashby B
Second Messengers Phosphoproteins; 1988; 12(1):45-57. PubMed ID: 2848122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
